# Neoantigen Identification Report

## Summary

Total neoantigens identified: 28
High-scoring neoantigens (score > 0.7): 21
Medium-scoring neoantigens (score 0.5-0.7): 5
HLA alleles analyzed: 10

## Top 20 Neoantigens

| Rank | Mutation ID | Wild Type | Mutant | Score | Expression | Best HLA |
|------|-------------|-----------|--------|-------|------------|----------|
| 1 | chr2_1500000_C_G... | HCFMTRSR | HCFMTRSR | 0.960 | 12.8 | HLA-C*07:01 |
| 2 | chr2_1500000_C_G... | MFKEYWFTADL | MFKEYWFTADL | 0.960 | 12.8 | HLA-B*08:01 |
| 3 | chr12_8000000_G_T... | NTGYRVSD | NTGYRVSD | 0.960 | 15.3 | HLA-C*07:02 |
| 4 | chr12_8000000_G_T... | KRNFDEHHKS | KRNFDEHHKS | 0.960 | 15.3 | HLA-B*07:02 |
| 5 | chr12_8000000_G_T... | TPPMDSGPLSA | TPPMDSGPLSA | 0.960 | 15.3 | HLA-A*02:01 |
| 6 | chr17_10000000_C_T... | EWVIFLAG | EWVIFLAG | 0.960 | 22.1 | HLA-B*07:02 |
| 7 | chr7_5000000_A_G... | PSHHDRVYKPD | PSHHDRVYKPD | 0.908 | 8.7 | HLA-B*07:02 |
| 8 | chr1_1000000_A_T... | DLCFLGKFK | DLCFFGKFK | 0.768 | 5.2 | HLA-C*07:01 |
| 9 | chr1_1000000_A_T... | HYEMVYHQEA | HYEMVYHQEA | 0.768 | 5.2 | HLA-B*07:02 |
| 10 | chr1_2000000_G_C... | NTEVECDP | NTEVECDP | 0.768 | 5.2 | HLA-A*02:01 |
| 11 | chr1_2000000_G_C... | RTQPLKSYI | RTQPLKSYI | 0.768 | 5.2 | HLA-A*02:01 |
| 12 | chr1_2000000_G_C... | SSTMATPWYKG | SSTMATPWYKG | 0.768 | 5.2 | HLA-A*02:01 |
| 13 | chr2_1500000_C_G... | TVDGNYTMT | TVDGNYTMT | 0.760 | 12.8 | HLA-A*01:01 |
| 14 | chr2_1500000_C_G... | PVEANVRVNI | PVEANVRVNI | 0.760 | 12.8 | HLA-A*01:01 |
| 15 | chr12_8000000_G_T... | DMPPTKNSL | DMPPTKNSL | 0.760 | 15.3 | HLA-A*02:01 |
| 16 | chr17_10000000_C_T... | SNANMAFRI | SNANMAFRI | 0.760 | 22.1 | HLA-A*02:01 |
| 17 | chr17_10000000_C_T... | LKMFQWDYPL | LKMFQWDYPL | 0.760 | 22.1 | HLA-A*01:01 |
| 18 | chr17_10000000_C_T... | DSKAYVVWNDF | DSKAYVVWNDF | 0.760 | 22.1 | HLA-A*02:01 |
| 19 | chr7_5000000_A_G... | MRITHWNS | MRITHWNS | 0.708 | 8.7 | HLA-C*07:01 |
| 20 | chr7_5000000_A_G... | MVQEMLYPC | MVQEMLYPC | 0.708 | 8.7 | HLA-C*07:01 |

## HLA Allele Analysis

| HLA Allele | Strong Binders | Weak Binders | Total Binders |
|------------|----------------|--------------|---------------|
| HLA-A*02:01 | 4 | 8 | 12 |
| HLA-A*01:01 | 2 | 16 | 18 |
| HLA-B*07:02 | 6 | 7 | 13 |
| HLA-B*08:01 | 4 | 7 | 11 |
| HLA-C*07:01 | 3 | 14 | 17 |
| HLA-C*07:02 | 4 | 8 | 12 |

## Recommendations

Excellent neoantigen landscape identified. Recommend selecting top 10-15 neoantigens for vaccine design.

Next steps:
1. Validate top neoantigens with experimental binding assays
2. Assess immunogenicity with T-cell activation assays
3. Design vaccine constructs incorporating selected neoantigens
4. Consider combination with checkpoint inhibitors
